Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;19(6):436-40.
doi: 10.5114/wo.2015.51824. Epub 2015 May 28.

Potential use of histone deacetylase inhibitors in cancer therapy

Karolina Gołąbek  1 , Joanna K Strzelczyk  1 , Andrzej Wiczkowski  1 , Marek Michalski  2
Affiliations
Review

Potential use of histone deacetylase inhibitors in cancer therapy

Karolina Gołąbek et al. Contemp Oncol (Pozn). 2015.

Abstract

Epigenetics is a branch of science that focuses on mechanisms related to control and modification of expression of genetic material without any changes to its sequences. Such mechanisms include post-translational modifications of histones. It is widely known that carcinogenesis is related to hypoacetylation of genes that influence apoptosis, the cell cycle, cell signaling, the immunologic response, angiogenesis and occurrence of metastasis. Currently conducted research focuses on several strategies related to epigenetic therapy. One such strategy is based on the use of histone deacetylase inhibitors. This paper presents mechanisms through which these compounds work and a summary of their characteristics. It also includes a review of clinical tests related to histone deacetylase inhibitors, as well as their relationship with other chemotherapeutic methods. A better understanding of the involved mechanisms will provide a rational basis to improve the therapeutic outcome of available antitumor agents.

Keywords: cancer therapy; epigenetics; histone deacetylase; histone deacetylase inhibitor.

PubMed Disclaimer

References

    1. Kwinta Ł. Epigenetyka czerniaka. Contemp Oncol (Pozn) 2008;2:45–50.
    1. Sigalotti L, Covre A, Fratta E, et al. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med. 2010;8:56. - PMC - PubMed
    1. Chen S, Sang N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol. 2011;2011:197946. doi: 10.1155/2011/197946. - DOI - PMC - PubMed
    1. Gillespie S, Borrow J, Zhang XD, Hersey P. Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis. 2006;11:2251–65. - PubMed
    1. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2005;11:71–6. - PubMed

LinkOut - more resources